The case for and concerns about continuous dopamine stimulation in Parkinson’s disease
Delivery of levodopa or other dopaminergic agents to the striatum is a critical determinant of the clinical response and may account for many of the fluctations in response (“on-off”). This should be manageable with innovative delivery systems for the drugs. However further studies are required to determine if continuous dopaminergic stimulation will be complicated by increased levels of drug metabolites or down regulation of dopaminergic neurotransmission.
KeywordsLarge Neutral Amino Acid Dopaminergic Agent Plasma Levodopa Continuous Dopaminergic Stimulation Plasma Dopa Level
Unable to display preview. Download preview PDF.
- Gervas JJ, Muradas V, Bazan E, Aguado EG, de Yebenes JG (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278–282Google Scholar
- McDowell RH, Papavasiliou P, Sweet R (1979) Long-term study and the effect of human growth hormone in parkinsonian patients treated with L-dopa. Adv Neurol 24: 475–488Google Scholar
- Nutt JG (1986) Food interactions in parkinsonism. Neurol Consult 3: 1–4Google Scholar
- Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-0-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 21: 584–588Google Scholar
- Pincus JH, Barry K (1986) Control of the “on-off” phenomenon with dietary manipulation. Ann Neurol 20: 149Google Scholar
- Reches A, Fahn S (1982) 3-0-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267–271Google Scholar
- Reches A, Mielke LR, Fahn S (1982) 3-0-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 32: 887–888Google Scholar
- Sharpless NS, Muenter MD, Tyce GM, Owen CA (1972) 3-methoxy-4-hydroxyphenyl- alanine (3-0-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson’s disease. Clin Chim Acta 37: 359–369Google Scholar